<?xml version="1.0" encoding="UTF-8"?>
<p id="p0410">The duration of ribavirin therapy in immunocompromised hosts is generally at least 3 days. Initiation of antiviral therapy at the stage of upper respiratory tract disease may decrease viral load and possibly reduce the risk of respiratory failure, although most data are based on retrospective uncontrolled data. </p>
